From OSN Europe

Stellaris Elite with Vitesse system receives CE mark

The European Commission has given a CE mark to Bausch + Lomb for the Stellaris Elite vision enhancement system with the Vitesse hypersonic open-port vitrectomy system, Valeant Pharmaceuticals announced in a press release.

The surgical platform is now available throughout Europe including Iceland, Liechtenstein, Norway and Switzerland, in addition to the 28 European Union countries. It is already available in the United States.

It is the first phacoemulsification platform available with adaptive fluidics, which combines aspiration control with predictive infusion management, the release said. The Vitesse system, which uses a single-needle design and continuously open-port system, is available exclusively on the Stellaris Elite platform.

“Because this surgical platform offers the opportunity to continuously add innovative upgrades and enhancements, it enables surgeons to customize their systems and expand their capabilities as their needs evolve without having to invest in a new surgical system,” Joseph C. Papa, chairman and CEO of Valeant, said in the release.

The European Commission has given a CE mark to Bausch + Lomb for the Stellaris Elite vision enhancement system with the Vitesse hypersonic open-port vitrectomy system, Valeant Pharmaceuticals announced in a press release.

The surgical platform is now available throughout Europe including Iceland, Liechtenstein, Norway and Switzerland, in addition to the 28 European Union countries. It is already available in the United States.

It is the first phacoemulsification platform available with adaptive fluidics, which combines aspiration control with predictive infusion management, the release said. The Vitesse system, which uses a single-needle design and continuously open-port system, is available exclusively on the Stellaris Elite platform.

“Because this surgical platform offers the opportunity to continuously add innovative upgrades and enhancements, it enables surgeons to customize their systems and expand their capabilities as their needs evolve without having to invest in a new surgical system,” Joseph C. Papa, chairman and CEO of Valeant, said in the release.